Novo Nordisk's Wegovy pill has rapidly expanded the GLP-1 weight loss drug market since its U.S. launch in January, doubling patient intake for telehealth providers and outperforming Eli Lilly's Foundayo pill introduced three months later. Wegovy's success is attributed to strong marketing, lower price, and high efficacy, attracting many new patients who prefer pills over injections. Eli Lilly is still building awareness for Foundayo, which has seen modest early uptake but shows potential for growth over time. Investors will watch Novo's upcoming earnings and market expansion plans, while both companies aim to capture a broader patient base with oral GLP-1 drugs.
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
The European Medicines Agency's CHMP has recommended approval of Novo Nordisk's Wegovy pill (oral semaglutide) for weight management in the EU. The pill showed a mean weight loss of 16.6% in trials, comparable to the injectable version, and also redu...
Deutsche Bank maintains a 'hold' rating on Novo Nordisk with a price target of DKK290 after discussions with the company's head of R&D. Novo Nordisk is cautiously optimistic about its new obesity drug study, cagrisema RD11, which may outperform the p...
